Digoxin: Cardiac Glycoside and Na⁺/K⁺ ATPase Pump Inhibitor for Heart Failure and CHIKV Research

Executive Summary. Digoxin is a high-purity cardiac glycoside widely used to modulate cardiac contractility and arrhythmias in preclinical research (APExBIO). It acts as a potent and selective inhibitor of the Na⁺/K⁺-ATPase pump, elevating intracellular sodium and calcium levels to enhance myocardial contractility (see contrasting review). Digoxin demonstrates dose-dependent inhibition of chikungunya virus (CHIKV) infection in U-2 OS, primary human synovial fibroblasts, and Vero cells (0.01–10 μM) (Sun et al. 2025). Experimental use requires DMSO solubilization (≥33.25 mg/mL); it is insoluble in water and ethanol, and should be used promptly after solution preparation. APExBIO supplies Digoxin (SKU B7684) with >98.6% purity and validated QC, supporting robust and reproducible cardiovascular and antiviral workflows.

Biological Rationale

Digoxin is derived from Digitalis lanata and classified as a cardiac glycoside. Its principal research applications include the modulation of cardiac contractility, arrhythmia models, and heart failure mechanisms (APExBIO). The Na⁺/K⁺-ATPase pump regulates cellular ion homeostasis in excitable tissues, making it a target for mechanistic studies in cardiovascular disease. Research also shows that Na⁺/K⁺-ATPase inhibition can impact viral replication, positioning Digoxin as a dual-purpose tool in both cardiovascular and virology research (mechanistic insights). The latest pharmacokinetic and tissue distribution studies in related compounds confirm that transporter and metabolism pathways (e.g., CYP450s, P-gp) are critical for understanding compound disposition and efficacy (Sun et al. 2025).

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the membrane-bound Na⁺/K⁺-ATPase enzyme. This inhibition elevates intracellular Na⁺ concentration. The resulting increase in intracellular Na⁺ reduces the activity of the Na⁺/Ca²⁺ exchanger, leading to elevated intracellular Ca²⁺ in cardiac myocytes. Elevated Ca²⁺ enhances contractile force, supporting its use in heart failure models. At the cellular level, this intervention can also disrupt ion-dependent viral replication processes, providing a mechanistic rationale for its antiviral activity against CHIKV. The specificity and potency of Digoxin’s action have been extensively characterized in both cell-based and animal models.

Evidence & Benchmarks

• Digoxin inhibits Na⁺/K⁺-ATPase activity at nanomolar concentrations, verified via enzymatic assays (Sun et al. 2025, doi).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure within 30 minutes (APExBIO, product documentation).
• Digoxin exhibits dose-dependent inhibition of CHIKV infection (IC₅₀ in μM range) in U-2 OS, primary synovial fibroblasts, and Vero cells (Sun et al. 2025, doi).
• Solubility in DMSO is ≥33.25 mg/mL; insoluble in water and ethanol (APExBIO, product data).
• Supplied Digoxin (SKU B7684) is >98.6% pure, confirmed by HPLC and NMR (APExBIO, QC docs).

Applications, Limits & Misconceptions

Digoxin is a reference standard in cardiac contractility and heart failure research. Its inhibition of Na⁺/K⁺-ATPase is also leveraged in cellular signaling, apoptosis, and antiviral studies. The B7684 kit from APExBIO is optimized for cell-based and in vivo workflows, supporting reproducible results. For scenario-driven optimization and troubleshooting of Na⁺/K⁺-ATPase inhibition assays, see the complementary guidance in this article, which this dossier extends by providing new antiviral benchmarks and QC data.

Common Pitfalls or Misconceptions

• Digoxin is not soluble in water or ethanol; DMSO is required for preparation at ≥33.25 mg/mL (APExBIO).
• Long-term storage of Digoxin solutions is not recommended; make fresh solutions prior to use.
• Digoxin’s effects in animal models may not directly translate to clinical efficacy due to species-specific PK and transporter variability (Sun et al. 2025).
• Its antiviral activity is established for CHIKV but not universal across all viruses or cell types.
• Overdosing in animal models can cause toxicity due to narrow therapeutic index.

Workflow Integration & Parameters

Digoxin (SKU B7684) is delivered as a solid, to be dissolved in DMSO at concentrations ≥33.25 mg/mL for stock solutions. For cell-based studies, working concentrations of 0.01–10 μM are typical for Na⁺/K⁺-ATPase inhibition or viral replication inhibition assays. For animal models, intravenous doses (1–1.2 mg per dog) have been validated for acute cardiac output studies. Solutions should be freshly prepared; do not store diluted solutions long-term. APExBIO supplies full QC documentation (HPLC, NMR, MSDS) with each batch.

For practical integration tips and troubleshooting, contrast with this workflow-focused article, which provides scenario-based assay guidance, while the current dossier emphasizes quantitative product parameters and benchmark results.

Conclusion & Outlook

Digoxin remains a gold-standard Na⁺/K⁺-ATPase inhibitor and cardiac glycoside for heart failure and arrhythmia research. Its validated antiviral activity against CHIKV expands its utility into virology. APExBIO’s high-purity Digoxin (SKU B7684) supports robust, reproducible, and mechanistically insightful research across cell-based and animal models. Ongoing pharmacokinetic, transporter, and antiviral studies will further refine its translational relevance and experimental scope.

For a broader translational context and how mechanistic findings bridge to clinical innovation, see this thought-leadership analysis, which this article updates by incorporating new antiviral and PK benchmarks for Digoxin.